Prostate cancer remains one of the most prevalent cancers among men, affecting approximately 1 in 8. Yet, many men are unaware of a critical test that could shape their treatment journey: PSMA PET imaging. In a recent educational initiative sponsored by Novartis, Dr. Phillip Koo, Executive Vice President and Chief Medical Officer at the Prostate Cancer Foundation, and Bill, a prostate cancer survivor and patient advocate, shed light on the significance of this scan and answered common questions.
Dr. Koo underscored the importance of early screening, noting that a simple blood test for prostate-specific antigen (PSA) has been used for decades to detect the disease early, maximizing the chances of successful outcomes, including a cure. He advised men to discuss this test with their doctors when appropriate. However, for those already diagnosed, PSMA testing offers a more detailed picture.
PSMA, or prostate-specific membrane antigen, is a protein found on the surface of prostate cancer cells. Using a PET scan, doctors can visualize whether cancer has spread beyond the prostate to other parts of the body. This information is vital for determining the next steps in care, as Dr. Koo explained: "PSMA is so important with regards to detecting disease and also determining the appropriate treatments that patients should receive down the road." Notably, 80-90% of prostate cancer patients express this biomarker, making the test broadly applicable.
Bill's personal experience underscores the value of proactive engagement. Diagnosed 18 years ago, he immediately sought knowledge and discovered PSMA testing through his own research. He brought the information to his doctor, and together they incorporated the scan into his treatment plan. "It helped me understand truly where I am in this journey," Bill said, adding that the results empowered him to take an active role in his care. After receiving his scan, he and his oncologist reviewed the results and crafted a plan of action, a process he describes as essential: "Information is power, and when you ask the questions and insist upon getting the right answers until you do get them is key to your success."
For patients and doctors, collaboration is crucial. Dr. Koo advised that patients must speak up and be heard, which requires educating themselves about the test. Knowing one's PSMA status is "vitally important to your cancer care," he emphasized, as it can guide treatment choices such as surgery, radiation, or newer targeted therapies.
The campaign directs men to visit GetYourScan.com for more information about PSMA testing and how to advocate for it. This resource aims to empower patients to have informed conversations with their healthcare providers.
The implications of this initiative are significant. For the medical community, it reinforces the value of precision medicine in oncology. For patients, it highlights the importance of being proactive in their care. With prostate cancer affecting millions globally, increased awareness of PSMA testing could lead to earlier, more tailored interventions, potentially improving survival rates and quality of life. As Bill's story shows, taking charge of one's health can make a profound difference.
